Windlas Biotech Delivers Robust H1FY27 Performance with Strong CDMO Growth
Windlas Biotech Ltd 路 Investor Presentation 路 05 Nov 2026, 10:31 pm
Windlas Biotech Delivers Robust H1FY27 Performance with Strong CDMO Growth Windlas Biotech reported Q2FY27 revenue of Rs. 264 Cr (+19% YoY) and H1FY27 revenue of Rs. 512 Cr (+18% YoY), driven by Generic Formulations CDMO surging 32% YoY to Rs. 422 Cr in H1FY27 (82% mix). H1FY27 adjusted EBITDA grew 23% YoY to Rs. 70 Cr (13.7% margin) and adjusted PAT rose 33% YoY to Rs. 50 Cr. Plant-6 was commercialized in Sep'26, while Plant-4 and Plant-5 received EU-GMP certifications. The company remains net-debt-free with Rs. 223 Cr net liquidity, delivering an H1FY27 annualized ROCE of 38%.
Original exchange filing (PDF)
More announcements from Windlas Biotech Ltd
- Q2 & H1 FY27 Earnings Conference Call Transcript 路 13 Nov 2026
- Recording of Conference Call 路 07 Nov 2026
- press release titled 'Windlas Biotech Limited Reports its H1 & Q2 FY27 Financial Results" 路 05 Nov 2026
- Mr. Ashok Kumar Windlass, has been appointed, as Founder President (Senior Management Personnel) of the Company, effective from November 6, 2026. 路 05 Nov 2026
- resignation of Mr. Ashok Kumar Windlass (DIN: 00011451) from the position of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M. 路 05 Nov 2026
- Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Approval inter alia unaudited financial results for the quarter and half year ended September 30, 2026 路 05 Nov 2026
- The Board approved inter alia financial results for the quarter and half year ended September 30 2026. 路 05 Nov 2026
